What a GLP-1 Telehealth Intake Actually Asks, and Why

Where the questions come from

An intake for these medications is mostly a label rendered as a form. Read the prescribing information for an approved GLP-1 and you will recognize nearly every question on the screen.

That framing changes how it feels to answer. The questions are not there to sell you something or to disqualify you on a technicality. They map to specific lines in a document a manufacturer had to get approved.

It also gives you a way to judge a program. An intake that skips the label's own contraindications is a shorter form than the medication's own documentation calls for, and that is a fact about the program.

The questions that come straight off the boxed warning

Both Wegovy and Zepbound carry a boxed warning about the risk of thyroid C-cell tumors. Wegovy's states that semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures, and that whether it does so in humans is unknown because the human relevance of that finding has not been determined.

The labels turn that into a contraindication. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma, and in patients with Multiple Endocrine Neoplasia syndrome type 2.

That is why an intake asks about your family's thyroid history and not only your own. The question is written the way the label is written.

Both labels also list known serious hypersensitivity to the active ingredient or to any excipient as a contraindication, which is the other question in this group.

The questions about what else you take

Concomitant medications matter here for a documented reason. Both labels warn that use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and note that reducing the dose of the insulin or secretagogue may be necessary.

Both labels also carry a limitation of use on stacking. Wegovy's states that concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Zepbound's says the same about other tirzepatide-containing products and any GLP-1 receptor agonist.

So the question about whether you are already taking one of these is not an upsell filter. It is on the form because the label says the combination is not recommended.

Wegovy's tablet form adds a timing instruction of its own, taken on an empty stomach in the morning with water, with at least 30 minutes before food, other drinks, or other oral medications. An intake that asks what else you take daily is asking a real question about that.

The history questions, and the conditions behind them

Pancreatitis appears in the warnings of both labels, which state that acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists and that treatment should be discontinued if it is suspected. A form asking about a history of pancreatitis is asking about that line.

Gallbladder disease is next to it. Both labels note acute gallbladder disease occurring in clinical trials and direct that gallbladder studies and clinical follow-up are indicated if a problem is suspected.

Gastroparesis has its own sentence. Both labels state that these medications are not recommended in patients with severe gastroparesis, within a broader warning about severe gastrointestinal adverse reactions.

Kidney function and diabetic retinopathy round out the group. The labels direct monitoring of renal function in patients reporting reactions that could lead to volume depletion. They also note that diabetic retinopathy complications have been reported in patients with type 2 diabetes. Patients with a history of diabetic retinopathy should be monitored.

The questions about pregnancy, and the one about surgery

Wegovy's label states that it may cause fetal harm, and directs that it be discontinued when pregnancy is recognized for patients taking it for cardiovascular risk reduction or weight reduction.

It goes further on planning. For those uses, the label directs discontinuing at least two months before a planned pregnancy, because of semaglutide's long half-life. That is why an intake asks about pregnancy plans rather than only about current pregnancy.

The label also states that breastfeeding is not recommended during treatment with Wegovy tablets.

Surgery is the question people are most surprised to see. Wegovy's label notes that pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective procedures. It instructs patients to inform their health care providers of any planned surgeries or procedures. An intake that asks about upcoming procedures is asking about that warning.

The questions that decide whether the medication is indicated

Height and weight are on the form because the approved indications are written in those terms. Wegovy injection is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.

Zepbound's weight indication is written the same way, for adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Both are indicated in combination with a reduced-calorie diet and increased physical activity.

That second clause is why an intake asks about other conditions. For someone in the overweight category, a weight-related condition is part of what the indication requires, so the question changes the answer.

Some indications are narrower still. Wegovy carries a cardiovascular risk reduction indication for adults with established cardiovascular disease and either obesity or overweight, and Zepbound carries one for moderate to severe obstructive sleep apnea in adults with obesity. A form asking about sleep apnea or cardiac history is asking which indication applies.

What a thin intake tells you

FDA publishes a list of warning signs for consumers using telehealth platforms, and two of them are about this exact moment. One is a company that does not require a screening and prescription by a licensed doctor before providing medicine.

The other is a company that does not have a licensed doctor available to answer questions after you receive your medication. Both are about whether a clinician is genuinely in the loop rather than at the end of a checkout flow.

So an intake that never asks about family thyroid history, pancreatitis, other GLP-1 use, or pregnancy plans is missing questions the labels themselves put in writing. Length alone is not quality, and a long form full of marketing questions is not better than a short clinical one.

Judge it by coverage against the label rather than by how many screens it took. The groups above are a reasonable checklist to hold a form against.

Answering it in a way that helps you

Answer completely, including the histories that feel unrelated. A form is the only clinical record some programs will have about you before a prescription is written.

Have your current medication list in front of you, with doses, including anything for diabetes. The hypoglycemia warning depends on that detail, and so does the limitation on combining these products.

Mention planned procedures, planned pregnancy, and any prior use of a GLP-1, even if no question asks. All three appear in the labeling and none of them always appears on a form.

Note who reviews the answers and how you reach that person afterward. FDA's own warning signs treat post-purchase clinical access as part of what a legitimate service provides.